The Food and Drug Administration (FDA) has granted expanded use of Eylea (aflibercept; Regeneron) injection to treat diabetic retinopathy in patients with diabetic macular edema (DME).

The safety and efficacy of Eylea to treat diabetic retinopathy in patients with DME were studied in 679 patients in two clinical studies. Patients were randomized to Eylea or macular laser photocoagulation. By week 100, patients treated with Eylea showed significant improvement in the severity of their diabetic retinopathy vs. patients who did not receive Eylea.

In 2014, the FDA granted Breakthrough Therapy designation and Priority Review for Eylea in the treatment of diabetic retinopathy in patients with DME. Eylea is already approved for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.

Eylea is available as a 2-mg single intravitreal injection.

For more information call (855) 395-3248 or visit Eylea.com.

This article originally appeared on MPR